Price
$0.243
Increased by +4.52%
Dollar Volume
1.06 M
ADR%
22.75
Market Cap.
3.51 M
Shares Float
9.28 M
Shares Outstanding
14.43 M
Beta
-0.00
Price / Earnings
-0.06
BPR
1.61
20D Range
0.20 0.47
50D Range
0.20 1.35
200D Range
0.20 3.33
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.68 -0.25
Decreased by -172.00%
Aug 22, 22 -0.52 -0.42
Decreased by -23.81%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-5.04 M
Decreased by -685.70%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-4.66 M
Decreased by -385.10%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00 - -4.65 M -
Decreased by N/A%
-
Dec 31, 21 0.00 - -4.97 M -
Decreased by N/A%
-
Sep 30, 21 0.00 - 860.00 K -
Increased by +N/A%
-
Sep 30, 20 0.00 - -960.00 K -
Decreased by N/A%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.